Retinal Disease

Electroretinogram changes after AntiVEGF pharmacotherapy in patients with retinal vein occlusion.

Status

Active, not recruiting

Phases

Phase 3Phase 4

Study type

Observational

Source

CTRI

Registry ID

CTRI/2018/04/012952

Enrollment

Registered

2018-04-03

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: NIL: NIL Control Intervention1: NIL: NIL

Eligibility

Inclusion criteria

Inclusion criteria: Patients diagnosed with RVO and has not taken any kind of treatment for the same are included in the study with a 6 months follow-up after AntiVEGF therapy

Exclusion criteria

Exclusion criteria: (a) Intraocular surgery including cataract extraction within 6 months before enrolment (b) Co-existing other retinal diseases (c) Previous laser photocoagulation (d) Intravitreal injection of Triamcinolone acetenoid or antivascular endothelial growth factory (Anti-VEGF) agents (e) prior ocular inflammation.

Design outcomes

Primary

Measure	Time frame
To study the ERG changes before and after AntiVEGF pharmacotherapy in patients with retinal vein occlusion.Timepoint: 12 months from the date of enrolment	—

Secondary

Measure	Time frame
Analysis of data for statistical record.Timepoint: 12 months from the date of enrolment	—

Countries

India

Contacts

Public ContactDr Mahesh G

Giridhar Eye Institute

go2roseg@yahoo.com9497625822

Outcome results